(RTTNews) - Boundless Bio Inc. (BOLD), a San Diego-based clinical-stage oncology company, Monday announced the appointment of Robert Doebele as Chief Medical Officer.
The company has been advancing its BBI-355 Phase 1/2 POTENTIATE trial and prepares to select a development candidate for its Kinesin program.
Doebele brings extensive experience in precision oncology, having co-founded Rain Oncology, Inc., where he had previously served as Chief Scientific and Medical Officer.
BOLD is currently trading at $2.31 up 0.87 percent or $0.02 on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
